SNSE
HEALTHCARESensei Biotherapeutics Inc
$26.02+0.16 (+0.62%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving SNSE Today?
No stock-specific AI insight has been generated for SNSE yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$5.26$36.76
$26.02
Fundamentals
Market Cap$32M
P/E Ratio—
EPS$-16.72
Dividend Yield—
Dividend / Share—
ROE-0.7%
Profit Margin—
Debt / Equity—
Trading
Volume22K
Avg Volume (10D)—
Shares Outstanding1.3M
SNSE News
16 articles- Sensei Biotherapeutics (SNSE): Best Performing NASDAQ Stocks According to Wall Street AnalystsYahoo Finance·May 5, 2026
- Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast CancerYahoo Finance·May 5, 2026
- Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare ConferenceYahoo Finance·Apr 9, 2026
- Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Mar 30, 2026
- Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Mar 17, 2026
- Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private PlacementYahoo Finance·Feb 18, 2026
- Egle Therapeutics Appoints John Celebi as Chief Executive OfficerYahoo Finance·Jan 7, 2026
- Sensei Biotherapeutics Reports Third Quarter 2025 Financial ResultsYahoo Finance·Nov 14, 2025
- Sensei to ditch its lead candidate and cut workforce amidst strategic reviewPharmaceutical-technology·Oct 31, 2025
- Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder ValueYahoo Finance·Oct 30, 2025
- Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025Yahoo Finance·Oct 17, 2025
- Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025Yahoo Finance·Sep 23, 2025
- Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceYahoo Finance·Sep 3, 2025
- Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Aug 5, 2025
- Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025Yahoo Finance·Jul 30, 2025
- Sensei Biotherapeutics Announces 1-for-20 Reverse Stock SplitYahoo Finance·Jun 13, 2025
All 16 articles loaded
Price Data
Open$27.70
Previous Close$25.86
Day High$27.70
Day Low$25.78
52 Week High$36.76
52 Week Low$5.26
52-Week Range
$5.26$36.76
$26.02
Fundamentals
Market Cap$32M
P/E Ratio—
EPS$-16.72
Dividend Yield—
Dividend / Share—
ROE-0.7%
Profit Margin—
Debt / Equity—
Trading
Volume22K
Avg Volume (10D)—
Shares Outstanding1.3M
About Sensei Biotherapeutics Inc
Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company, is dedicated to the discovery and development of therapies with an initial focus on cancer treatments. The company is headquartered in Rockville, Maryland.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—